慢性肾脏病患者口服抗凝药物临床应用的研究进展
Research Progress on the Clinical Application of Oral Anticoagulants in Patients with Chronic Kidney Disease
DOI: 10.12677/ACM.2023.1361309, PDF,    科研立项经费支持
作者: 杨富蓉, 周晓倩, 杨松烨, 翁稚颖*：昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明；钱懿轶, 陈韦兆：云南省阜外心血管病医院药剂科，云南 昆明
关键词: 慢性肾脏病；CVD；抗凝相关性肾病；华法林；NOACs；Chronic Kidney Disease； CVD； Anticoagulation-Associated Nephropathy； Warfarin； NOACs
摘要: 慢性肾脏病(chronic kidney disease, CKD)已然成为一个全球公认的公共卫生问题，普遍认为CKD和心脑血管疾病(cerebrovascular disease, CVD)会互相影响彼此相关的结局，合理管理CVD可以延缓CKD病情进展，随着维生素K拮抗剂华法林的广泛应用和新型口服抗凝药物的引入，在预防血栓栓塞发生的同时也可能增加并发肾损伤的风险，并且在晚期CKD患者中，口服抗凝药的应用以及根据肾功能进行剂量调整的争议依然存在。本文对目前CKD患者口服抗凝药物的应用进行综述，旨在为肾功能受损患者提供个性化的治疗决策。
Abstract: Chronic kidney disease (CKD) has become a globally recognized public health problem, it is gener-ally believed that CKD and cerebrovascular disease (CVD) will affect each other in related outcomes, reasonable management of CVD can delay the progression of CKD, with the widespread use of the vitamin K antagonist warfarin and the introduction of new oral anticoagulants, while preventing thromboembolism, it may also increase the risk of concurrent renal injury, and the use of oral anti-coagulants and dose adjustment according to renal function remain controversial in patients with advanced CKD. This article reviews the current use of oral anticoagulants in patients with CKD, aiming to provide personalized treatment decisions for patients with impaired renal function.
文章引用：杨富蓉, 钱懿轶, 周晓倩, 杨松烨, 陈韦兆, 翁稚颖. 慢性肾脏病患者口服抗凝药物临床应用的研究进展[J]. 临床医学进展, 2023, 13(6): 9356-9362. https://doi.org/10.12677/ACM.2023.1361309

参考文献

[1] 高翔, 梅长林. 《慢性肾脏病早期筛查、诊断及防治指南(2022年版)》解读[J]. 中国实用内科杂志, 2022, 42(9): 735-739.
[2] Zhuang, Z., Tong, M., Clarke, R., et al. (2022) Probability of Chronic Kidney Disease and Associated Risk Factors in Chinese Adults: A Cross-Sectional Study of 9 Million Chinese Adults in the Meinian Onehealth Screen-ing Survey. Clinical Kidney Journal, 15, 2228-2236. [Google Scholar] [CrossRef] [PubMed]
[3] Matsushita, K., van der Velde, M., Astor, B.C., et al. (2010) Association of Estimated Glomerular Filtration Rate and Albuminuria with All-Cause and Cardiovascular Mortality in General Population Cohorts: A Collaborative Meta-Analysis. The Lancet, 375, 2073-2081. [Google Scholar] [CrossRef] 
[4] GBD 2019 Stroke Collaborators (2021) Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 20, 795-820.
[5] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版) [J]. 中华肾脏病杂志, 2022, 38(5): 453-464.
[6] Ene-Iordache, B., Perico, N., Bikbov, B., et al. (2016) Chronic Kidney Disease and Cardiovascular Risk in Six Regions of the World (ISN-KDDC): A Cross-Sectional Study. The Lancet Global Health, 4, e307-e319. [Google Scholar] [CrossRef] 
[7] Zhang, L., Wang, F., Wang, L., et al. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 379, 815-822. [Google Scholar] [CrossRef] 
[8] Saran, R., Robinson, B., Abbott, K.C., et al. (2020) US Re-nal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 75, A6-A7. [Google Scholar] [CrossRef] [PubMed]
[9] Kelly, D.M., Ademi, Z., Doehner, W., et al. (2021) Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance from a KDIGO Controversies Conference. Stroke, 52, e328-e346. [Google Scholar] [CrossRef] 
[10] Shroff, G.R., Stoecker, R. and Hart, A. (2018) Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients with CKD: Pragmatic Considerations for the Clinician. American Journal of Kidney Diseases, 72, 717-727. [Google Scholar] [CrossRef] [PubMed]
[11] Schwartzenberg, S., Lev, E.I., Sagie, A., et al. (2016) The Quan-dary of Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease. American Journal of Car-diology, 117, 477-482. [Google Scholar] [CrossRef] [PubMed]
[12] Andrassy, K.M. (2013) Comments on “KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease”. Kidney International, 84, 622-623. [Google Scholar] [CrossRef] [PubMed]
[13] 史永红, 张春东, 吴广礼. 抗凝相关性肾病发病及高危因素研究进展[J]. 临床误诊误治, 2021, 34(10): 113-116.
[14] Reilly, E.B., Perry, A., Fujita, K., et al. (1964) Haematuria and Anti-coagulants. The Lancet, 1, 554. [Google Scholar] [CrossRef] 
[15] Li, J., Padala, S.A., Hinnant, G., et al. (2019) My Bleeding Nephrons! Journal of Investigative Medicine High Impact Case Reports, 7. [Google Scholar] [CrossRef] [PubMed]
[16] Chen, S., Liao, D., Yang, M., et al. (2023) Anticoagulant-Related Nephropathy Induced by Direct-Acting Oral Anticoagulants: Clinical Characteristics, Treatments and Outcomes. Throm-bosis Research, 222, 20-23. [Google Scholar] [CrossRef] [PubMed]
[17] Trujillo, H., Sandino, J., Cavero, T., et al. (2022) IgA Nephropathy Is the Most Common Underlying Disease in Patients with Anticoagulant-Related Nephropathy. Kidney In-ternational Reports, 7, 831-840. [Google Scholar] [CrossRef] [PubMed]
[18] Belcic, M.T., Kojc, N., Frelih, M., et al. (2021) Management of Anticoagulant-Related Nephropathy: A Single Center Experience. Journal of Clinical Medicine, 10, Article No. 796. [Google Scholar] [CrossRef] [PubMed]
[19] Zeni, L., Manenti, C., Fisogni, S., et al. (2020) Acute Kidney Injury Due to Anticoagulant-Related Nephropathy: A Suggestion for Therapy. Case Reports in Nephrology, 2020, Article ID: 8952670. [Google Scholar] [CrossRef] [PubMed]
[20] Wheeler, D.S., Giugliano, R.P. and Rangaswami, J. (2016) Anticoagu-lation-Related Nephropathy. Journal of Thrombosis and Haemostasis, 14, 461-467. [Google Scholar] [CrossRef] [PubMed]
[21] Brodsky, S.V., Nadasdy, T., Rovin, B.H., et al. (2011) Warfarin-Related Nephropathy Occurs in Patients with and without Chronic Kidney Disease and Is Associated with an Increased Mortality Rate. Kidney International, 80, 181-189. [Google Scholar] [CrossRef] [PubMed]
[22] Quinn, L.M., Richardson, R., Cameron, K.J., et al. (2015) Evaluating Time in Therapeutic Range for Hemodialysis Patients Taking Warfarin. Clinical Nephrology, 83, 80-85. [Google Scholar] [CrossRef] 
[23] Bonde, A.N., Lip, G.Y., Kamper, A.L., et al. (2016) Renal Function and the Risk of Stroke and Bleeding in Patients with Atrial Fibrillation: An Observational Cohort Study. Stroke, 47, 2707-2713. [Google Scholar] [CrossRef] 
[24] Chang, S.H., Wu, C.V., Yeh, Y.H., et al. (2019) Efficacy and Safety of Oral Anticoagulants in Patients with Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease. The American Journal of Medicine, 132, 1335-1343. [Google Scholar] [CrossRef] [PubMed]
[25] Altawalbeh, S.M., Alshogran, O.Y. and Smith, K.J. (2018) Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value in Health, 21, 1365-1372. [Google Scholar] [CrossRef] [PubMed]
[26] Ning, X., Kuang, Y., Yang, G., et al. (2021) Influence of Renal In-sufficiency on Anticoagulant Effects and Safety of Warfarin in Chinese Patients: Analysis from a Randomized Controlled Trial. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394, 1275-1283. [Google Scholar] [CrossRef] [PubMed]
[27] Reinecke, H., Nabauer, M., Gerth, A., et al. (2015) Morbidity and Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. Kidney International, 87, 200-209. [Google Scholar] [CrossRef] [PubMed]
[28] Goto, S., Angchaisuksiri, P., Bassand, J.P., et al. (2019) Management and 1-Year Outcomes of Patients with Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results from the Prospective GARFIELD-AF Registry. Journal of the American Heart Association, 8, e10510.
[29] Kruger, T. and Floege, J. (2014) Vitamin K Antagonists: Beyond Bleeding. Seminars in Dialysis, 27, 37-41. [Google Scholar] [CrossRef] [PubMed]
[30] January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Re-port of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 74, 104-132. [Google Scholar] [CrossRef] [PubMed]
[31] Obrezan, A.G. and Zemchenkov, A.Y. (2018) Chronic Kidney Disease as Basis of High Thrombotic and Bleeding Risk in Patients with Atrial Fibrillation: Place of Oral Anticoagulants. Kardiologiia, 58, 60-70. [Google Scholar] [CrossRef] [PubMed]
[32] Diener, H.C., Aisenberg, J., Ansell, J., et al. (2017) Choosing a Particular Oral Anticoagulant and Dose for Stroke Prevention in Individual Patients with Non-Valvular Atrial Fibrillation: Part 2. European Heart Journal, 38, 860-868. [Google Scholar] [CrossRef] [PubMed]
[33] Mlodawska, E., Lopatowska, P., Malyszko, J., et al. (2018) Atrial Fibrillation in Dialysis Patients: Is There a Place for Non-Vitamin K Antagonist Oral Anticoagulants? International Urology and Nephrology, 50, 1633-1642. [Google Scholar] [CrossRef] [PubMed]
[34] Steffel, J., Collins, R., Antz, M., et al. (2021) 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 23, 1612-1676. [Google Scholar] [CrossRef] [PubMed]
[35] Ha, J.T., Neuen, B.L., Cheng, L.P., et al. (2019) Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Annals of Internal Medicine, 171, 181-189. [Google Scholar] [CrossRef] 
[36] Rossini, R., Casula, M. and Ferlini, M. (2021) Atrial Fibrillation in Ad-vanced Renal Failure: Are There Alternative Solutions to Warfarin-Dicumarol? European Heart Journal Supplements, 23, E138-E141. [Google Scholar] [CrossRef] [PubMed]
[37] Maegdefessel, L., Spin, J.M., Azuma, J., et al. (2010) New Options with Dabigatran Etexilate in Anticoagulant Therapy. Vascular Health and Risk Management, 6, 339-349. [Google Scholar] [CrossRef] 
[38] Pollack, C.J., Reilly, P.A., van Ryn, J., et al. (2017) Idarucizumab for Dabigatran Reversal—Full Cohort Analysis. The New England Journal of Medicine, 377, 431-441. [Google Scholar] [CrossRef] 
[39] Ravera, M., Bussalino, E., Fusaro, M., et al. (2020) Systematic DOACs Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease: The Nephrologist’s Per-spective. Journal of Nephrology, 33, 483-495. [Google Scholar] [CrossRef] [PubMed]
[40] See, L.C., Lee, H.F., Chao, T.F., et al. (2021) Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Popula-tion-Based Cohort Study and Meta-Analysis. Cardiovascular Drugs and Therapy, 35, 975-986. [Google Scholar] [CrossRef] [PubMed]

为你推荐